Acumen Pharmaceuticals, Inc. (ABOS) News
Filter ABOS News Items
ABOS News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
ABOS News Highlights
- ABOS's 30 day story count now stands at 3.
- Over the past 7 days, the trend for ABOS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ABOS are III, AMP and DRUG.
Latest ABOS News From Around the Web
Below are the latest news stories about ACUMEN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ABOS as an investment opportunity.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript May 14, 2023 Operator: Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast. At this time all participants are in a listen-only mode. After the speaker’s presentation there’ll be a question-and-answer session. [Operator Instructions] Please be […] |
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Conference Call May 09, 2023, 08:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO and Chief Business Officer Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - BofA Presentation Operator Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast. At this time all participants are in a listen-only mode. After the speaker’s presentation there’ll be a question-and-answer session. [Operator Instructions] Plea... |
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business HighlightsExpect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support clinical and operational activities through 2025Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and Carmel, Ind., May 09, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. ( |
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare ConferenceCHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2023 Bank of America Healthcare Conference on Thursday, May 11, 2023 at 8:00 a.m. PT (11:00 a.m. ET). The live webcast may be accessed under t |
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET t |
Institutions own 26% of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares but private equity firms control 42% of the companyKey Insights Acumen Pharmaceuticals' significant private equity firms ownership suggests that the key decisions are... |
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript March 27, 2023 Operator: Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today’s conference […] |
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s DiseaseData describe induced pluripotent stem cell (iPSC)-derived excitatory neurons as a human model for assessing selectivity of drug binding to soluble amyloid beta oligomers in Alzheimer’s diseaseResults provide evidence that oligomer size may influence neuronal binding and detection, and substantiate the importance of oligomer preparation and antibody selection in assay resultsPoster presented at AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurologi |
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business HighlightsINTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash equivalents and marketable securities of $193.4 million as of Dec. 31, 2022 expected to be sufficient to support clinical and operational goals through 2025Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and CARMEL, Ind., March 27, 2023 (GLOBE NEWSWIRE) -- Acumen Phar |
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS DaysCHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Wednesday, March 29, 2023 at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on www. |